Time-Restricted Eating and Staple Food Reduction Combined With App-Supported Exercise for Weight and Glycemic Control (TRE-SFR-EX)
tiistai 21. heinäkuuta 2026 päivittänyt: Peking University
A Multicenter Randomized Controlled Trial of Time-Restricted Eating, Staple Food Reduction, and App-Supported Exercise for Weight Loss and Glycemic Improvement in Adults With Obesity and Abnormal Glucose Metabolism
This multicenter, three-arm randomized controlled trial will evaluate the effects of early time-restricted eating and staple food reduction, each combined with an app-supported exercise intervention, on body weight and glycemic control among adults with obesity and abnormal glucose metabolism.
A total of 300 participants aged 18 to 50 years with BMI >=28 kg/m2 and impaired glucose regulation or diabetes will be enrolled at five centers in China and randomized 1:1:1 to app-supported exercise alone, staple food reduction plus app-supported exercise, or early time-restricted eating plus app-supported exercise.
The intervention lasts 12 weeks, followed by a 12-week post-intervention follow-up.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Yksityiskohtainen kuvaus
All groups will use the Xiangdong Health app for exercise prescriptions, self-monitoring, and behavioral feedback.
The staple food reduction group will reduce staple food intake by approximately one half at three meals without restriction of eating time.
The early time-restricted eating group will consume food only between 07:00 and 15:00, with water allowed outside the eating window, without prescribed restriction of total daily energy intake.
Outcomes will be measured at baseline, week 12, and week 24, including body weight, glycemic indices, continuous glucose monitoring metrics, body composition, blood pressure, blood biochemistry, urine tests, stool microbiome, dietary recall, physical activity, sleep, appetite, psychological measures, adherence, and adverse events.
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
300
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Age 18 to 50 years, all sexes.
- Body mass index (BMI) >=28 kg/m2.
- Willing and able to comply with study procedures and provide written informed consent.
- Resident living near a participating study site and able to complete scheduled visits.
- No habitual time-restricted eating or other fasting regimen, such as alternate-day fasting or fasting-mimicking diet.
- Abnormal glucose metabolism or diabetes, defined as fasting plasma glucose >5.6 mmol/L or HbA1c >5.7%.
Exclusion Criteria:
- Secondary obesity, such as hypothyroidism or Cushing syndrome.
- Use of weight-loss medication within 90 days before screening, or body weight change >5 kg within 90 days before screening.
- Pregnant, lactating, or planning pregnancy during the study period.
- Severe cardiac, hepatic, or renal dysfunction.
- Severe psychiatric disease or cognitive impairment that prevents cooperation with the study.
- Contraindication to exercise, such as severe osteoarthritis.
- Unable or unwilling to follow the study diet and exercise intervention.
- Long-term use of medications that may significantly affect body weight.
- Active malignancy in any organ system.
- Any other condition that, in the investigator's judgment, may affect efficacy or safety evaluation or make the participant unsuitable for the study.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: App-Supported Exercise
Participants receive exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks.
The program includes progressive aerobic exercise, resistance training, flexibility training, and balance training.
|
Participants receive individualized exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks.
The exercise program includes progressive aerobic exercise, resistance training, flexibility training, and balance training.
|
|
Kokeellinen: Staple Food Reduction Plus App-Supported Exercise
Participants reduce staple food intake by approximately one half at three meals without restriction of eating time and receive the same app-supported exercise intervention for 12 weeks.
|
Participants receive individualized exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks.
The exercise program includes progressive aerobic exercise, resistance training, flexibility training, and balance training.
Participants reduce staple food intake by approximately one half at three meals without restriction of eating time.
This dietary strategy is combined with the same app-supported exercise intervention.
|
|
Kokeellinen: Early Time-Restricted Eating Plus App-Supported Exercise
Participants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window, without prescribed restriction of total daily energy intake, and receive the same app-supported exercise intervention for 12 weeks.
|
Participants receive individualized exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks.
The exercise program includes progressive aerobic exercise, resistance training, flexibility training, and balance training.
Participants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window.
Total daily energy intake is not prescribed, and participants are advised to follow the Chinese Dietary Guidelines.
This dietary strategy is combined with the same app-supported exercise intervention.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in body weight from baseline to week 12
Aikaikkuna: Baseline and week 12
|
Body weight will be measured using a calibrated scale.
The primary analysis will compare absolute change in body weight from baseline to week 12 among the three randomized groups.
|
Baseline and week 12
|
|
Change in CGM-derived glucose exposure and time in range from baseline to week 12
Aikaikkuna: Baseline and week 12
|
Continuous glucose monitoring (CGM) metrics will include glucose area under the curve and time in range (TIR), defined as the percentage of valid CGM readings between 3.9 and 10.0 mmol/L.
Changes from baseline to week 12 will be compared among the three randomized groups.
|
Baseline and week 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in BMI from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Calculated as weight in kg divided by height in meters squared (kg/m²).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in body fat mass from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Change in body fat mass (measured in kilograms, kg) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
|
Baseline, week 12, and week 24
|
|
Change in fasting plasma glucose from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting plasma glucose will be measured in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in systolic blood pressure from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Systolic blood pressure will be measured in millimeters of mercury (mmHg).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in CGM-derived mean glucose from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Mean glucose will be calculated from valid CGM readings and reported in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in questionnaire-based behavioral and patient-reported measures from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Questionnaire-based measures include dietary intake, physical activity, sleep, psychological status, appetite, and intervention adherence.
|
Baseline, week 12, and week 24
|
|
Adverse events and serious adverse events
Aikaikkuna: From baseline through week 24
|
Adverse events and serious adverse events will be collected throughout the intervention and follow-up period and summarized by randomized group.
|
From baseline through week 24
|
|
Change in Waist circumference from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Measured in centimeters (cm).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in Hip circumference from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Measured in centimeters (cm).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in Waist-to-hip ratio (WHR) from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Calculated as a unitless ratio.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in body fat percentage from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Change in body fat percentage (measured in %) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
|
Baseline, week 12, and week 24
|
|
Change in skeletal muscle mass from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Change in skeletal muscle mass (measured in kilograms, kg) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
|
Baseline, week 12, and week 24
|
|
Change in glycated hemoglobin (HbA1c) from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Glycated hemoglobin (HbA1c) will be measured as a percentage.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in fasting plasma insulin from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting plasma insulin will be measured in microunits per milliliter (µIU/mL).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in homeostatic model assessment of insulin resistance from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will be calculated from fasting plasma glucose and fasting plasma insulin and reported as a unitless index.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in diastolic blood pressure from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Diastolic blood pressure will be measured in millimeters of mercury (mmHg).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in heart rate from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Heart rate will be measured in beats per minute (bpm).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in total cholesterol from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting serum total cholesterol will be measured in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in triglycerides from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting serum triglycerides will be measured in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in low-density lipoprotein cholesterol from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting serum low-density lipoprotein cholesterol (LDL-C) will be measured in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in high-density lipoprotein cholesterol from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Fasting serum high-density lipoprotein cholesterol (HDL-C) will be measured in millimoles per liter (mmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in alanine aminotransferase from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Serum alanine aminotransferase (ALT) will be measured in units per liter (U/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in aspartate aminotransferase from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Serum aspartate aminotransferase (AST) will be measured in units per liter (U/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in serum creatinine from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Serum creatinine will be measured in micromoles per liter (µmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in serum uric acid from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Serum uric acid will be measured in micromoles per liter (µmol/L).
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in CGM-derived time above range from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Time above range (TAR) will be calculated as the percentage of valid CGM readings above 10.0 mmol/L.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in CGM-derived time below range from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
Time below range (TBR) will be calculated as the percentage of valid CGM readings below 3.9 mmol/L.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
|
Change in CGM-derived glucose coefficient of variation from baseline to week 12 and week 24
Aikaikkuna: Baseline, week 12, and week 24
|
The glucose coefficient of variation (CV) will be calculated from valid CGM readings and reported as a percentage.
Changes will be compared among the three randomized groups.
|
Baseline, week 12, and week 24
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Keskiviikko 1. heinäkuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. joulukuuta 2026
Opintojen valmistuminen (Arvioitu)
Torstai 1. huhtikuuta 2027
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Maanantai 13. heinäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 21. heinäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Perjantai 24. heinäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Perjantai 24. heinäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 21. heinäkuuta 2026
Viimeksi vahvistettu
Keskiviikko 1. heinäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Endokriinisen järjestelmän sairaudet
- Ravitsemushäiriöt
- Metaboliset sairaudet
- Yliravitsemus
- Kehon paino
- Glukoosiaineenvaihduntahäiriöt
- Diabetes mellitus
- Ylipainoinen
- Patologiset tilat, merkit ja oireet
- Käyttäytyminen
- Ravitsemukselliset ja aineenvaihduntataudit
- Merkit ja oireet
- Ruokintakäyttäytyminen
- Paasto
- Lihavuus
- Diabetes mellitus, tyyppi 2
- Prediabeettinen tila
- Ajoittainen paasto
Muut tutkimustunnusnumerot
- IRB00001052-26093
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
IPD-suunnitelman kuvaus
Individual participant data will not be shared publicly because the study includes sensitive health information and biological sample data.
De-identified aggregate results will be reported in scientific publications.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .